Brünner N, Spang-Thomsen M, Vindeløv L, Wolff J, Engelholm S A
Eur J Cancer Clin Oncol. 1985 Nov;21(11):1349-54. doi: 10.1016/0277-5379(85)90316-5.
A study was made of the in vivo effect of the anti-oestrogen tamoxifen on the growth and cell cycle kinetics of the oestrogen and progesterone receptor-positive T61 human breast carcinoma and of the oestrogen and progesterone receptor-negative T60 human breast carcinoma grown in nude mice. The T61 tumour was exposed to single doses of 0.1, 1.0, 5 or 10 mg tamoxifen, resulting in serum concentrations 1 day after treatment ranging from less than 27 to 134 nM. The T60 tumour was exposed to a single dose of 1.0 mg tamoxifen. The effect on the tumour growth curves was determined according to a transformed Gompertz function, and the effect on the cell cycle distributions was estimated by flow cytometric DNA analysis on tumour tissue obtained by fine-needle aspirations at intervals after the treatment. The results showed that in the T61 tumour, tamoxifen induced a dose-related growth inhibition, whereas it had no concomitant effect on the cell cycle distribution of the tumour. The treatment had no effect on the T60 tumour. The results indicate that tamoxifen is unsuitable as a synchronizing agent in human breast tumours with responses to the drug similar to those of the T61 and T60 breast tumours.
一项关于抗雌激素他莫昔芬对雌激素和孕激素受体阳性的T61人乳腺癌以及雌激素和孕激素受体阴性的T60人乳腺癌在裸鼠体内生长和细胞周期动力学影响的研究。将T61肿瘤暴露于0.1、1.0、5或10 mg单剂量的他莫昔芬，治疗后1天血清浓度范围为低于27至134 nM。将T60肿瘤暴露于1.0 mg单剂量的他莫昔芬。根据转化的Gompertz函数确定对肿瘤生长曲线的影响，并通过对治疗后不同时间间隔经细针穿刺获得的肿瘤组织进行流式细胞术DNA分析来估计对细胞周期分布的影响。结果显示，在T61肿瘤中，他莫昔芬诱导了剂量相关的生长抑制，而对肿瘤的细胞周期分布没有伴随影响。该治疗对T60肿瘤没有作用。结果表明，他莫昔芬不适用于对该药物反应与T61和T60乳腺肿瘤相似的人乳腺肿瘤作为同步剂。
